002390.SHE Guizhou Xinbang Pharmaceutical Co Ltd
- Market cap
- CNY 6.06B
- P/E
- 44.6x
- P/B
- 0.88x
- ROE
- 3.6%
- Dividend yield
- 3.17%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is 002390.SHE undervalued?
Graham number002390.SHE trades 32.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guizhou Xinbang Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Guizhou Xinbang Pharmaceutical Co Ltd yet.
Guizhou Xinbang Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guizhou Xinbang Pharmaceutical Co Ltd
Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally. The company cardiovascular and cerebrovascular, digestive system, endocrine, tumors and immunomodulatory drugs, blood system drugs, rheumatism and rheumatoid arthritis, urinary system, antipyretic and analgesic, cold medicine, gynecological, and anti-infective drugs and medications. It also provides medical services. The…
Full company profileGuizhou Xinbang Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guizhou Xinbang Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.18B | 5.16B | 6.00B | 6.58B | 6.66B | 5.85B | 6.47B | 6.35B | 6.46B | 6.03B | 4.80B |
| Gross Profit | 861M | 1.11B | 1.26B | 1.43B | 1.46B | 1.25B | 1.35B | 1.22B | 1.22B | 1.03B | 846M |
| Operating Income | 184M | 227M | 422M | -1.20B | 345M | 287M | 452M | 316M | 385M | 255M | 366M |
| EBITDA | 418M | 471M | 665M | 662M | 714M | 635M | 767M | 568M | 620M | 491M | 404M |
| Net Income | 174M | 246M | 319M | -1.30B | 236M | 174M | 273M | 224M | 287M | 101M | 244M |
| EPS | 0.14 | 0.15 | 0.19 | -0.80 | 0.15 | 0.11 | 0.15 | 0.12 | 0.15 | 0.05 | 0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 6.50B | 10.8B | 12.0B | 10.9B | 10.4B | 9.66B | 9.63B | 9.79B | 9.24B | 9.03B | 8.43B |
| Total Liabilities | 3.84B | 4.31B | 5.20B | 5.69B | 5.37B | 4.49B | 2.80B | 2.73B | 2.10B | 2.01B | 1.38B |
| Shareholders' Equity | 2.54B | 6.35B | 6.62B | 4.97B | 4.84B | 4.92B | 6.62B | 6.81B | 6.85B | 6.71B | 6.77B |
| Cash & Short-term Investments | 655M | 1.81B | 2.23B | 1.61B | 1.24B | 1.78B | 625M | 899M | 806M | 1.02B | 1.48B |
| Total Debt | 2.36B | 2.79B | 3.69B | 4.20B | 3.76B | 3.38B | 1.39B | 1.37B | 817M | 773M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 217M | -199M | 202M | -219M | 886M | 742M | 458M | 591M | 791M | 635M | - |
| Capital Expenditure | 492M | 432M | 435M | 264M | 208M | 138M | 254M | 159M | 136M | 125M | 47.8M |
| Free Cash Flow | -275M | -631M | -233M | -482M | 679M | 604M | 204M | 432M | 655M | 510M | 1.13B |
| Ratios | |||||||||||
| ROE | 6.9% | 3.9% | 4.8% | -26.1% | 4.9% | 3.5% | 4.1% | 3.3% | 4.2% | 1.5% | 3.6% |
| ROA | 2.7% | 2.3% | 2.7% | -11.9% | 2.3% | 1.8% | 2.8% | 2.3% | 3.1% | 1.1% | 2.9% |
| Net Profit Margin | 4.2% | 4.8% | 5.3% | -19.7% | 3.6% | 3.0% | 4.2% | 3.5% | 4.4% | 1.7% | 5.1% |
| Debt to Equity | 0.93x | 0.44x | 0.56x | 0.85x | 0.78x | 0.69x | 0.21x | 0.20x | 0.12x | 0.12x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guizhou Xinbang Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.17%
- Forward dividend
- 0.09 CNY
- Payout ratio
- 189.7%
- Ex-dividend date
- Sep 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | CNY 192M | 0.10 | 189.7% |
| 2023 | CNY 117M | 0.06 | 40.6% |
| 2022 | CNY 168M | 0.09 | 75.0% |
| 2021 | CNY 230M | 0.13 | 84.4% |
| 2020 | CNY 198M | 0.12 | 113.9% |
| 2019 | CNY 207M | 0.13 | 87.6% |
| 2018 | CNY 253M | 0.16 | - |
| 2017 | CNY 186M | 0.11 | 58.2% |
| 2016 | CNY 180M | 0.11 | 73.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 25:10 on May 25, 2015.
Who owns Guizhou Xinbang Pharmaceutical Co Ltd
- Insiders 46.07%
- Institutions 1.03%
- Public & others 52.90%
- Shares outstanding 1.94B
- Free float 1.02B
Guizhou Xinbang Pharmaceutical Co Ltd company profile
- Company name
- Guizhou Xinbang Pharmaceutical Co Ltd
- Ticker
- 002390.SHE
- ISIN
- CNE100000NG5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 16, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,702
- Fiscal year end
- December
- Address
- Kekai No.1 Courtyard, Guiyang, China, 550018
- Phone
- 86 851 8866 0239
- Website
- xinbang.com
About Guizhou Xinbang Pharmaceutical Co Ltd
Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally. The company cardiovascular and cerebrovascular, digestive system, endocrine, tumors and immunomodulatory drugs, blood system drugs, rheumatism and rheumatoid arthritis, urinary system, antipyretic and analgesic, cold medicine, gynecological, and anti-infective drugs and medications. It also provides medical services. The company was founded in 1995 and is headquartered in Guiyang, China.
Guizhou Xinbang Pharmaceutical Co Ltd management
7- Ms. Lingzhong KongGM & Director · born 1968
- Ms. Yajun Xiao CPACFO & Deputy GM · born 1973
- Ms. Yafang LuDeputy General Manager · born 1969
- Ms. Chuan ChenDeputy GM & Secretary of the Board · born 1969
- Mr. Zhangjie QingDeputy General Manager · born 1975
- Mr. Chi LuoDeputy General Manager · born 1990
- Juan LiaoAccounting Supervisor & Head of Accounting Department